Cytoreductive surgery and sandwich therapy with chemohyperthermic peritoneal perfusion and intra-aortic chemotherapy for peritoneal dissemination in gastric cancer

  • Authors:
    • T Fujimura
    • Y Yonemura
    • T Kawamura
    • N Nojima
    • T Satoh
    • Y Hirono
    • S Kinami
    • S Fushida
    • G Nishimura
    • K Miwa
    • I Miyazaki
  • View Affiliations

  • Published online on: May 1, 1996     https://doi.org/10.3892/or.3.3.513
  • Pages: 513-517
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Cytoreductive resection (RST), chemohyperthermic peritoneal perfusion (CHPP) and/or intra-aortic chemotherapy (IA-chemo) were performed for peritoneal dissemination in gastric cancer. Ninety-six patients with peritoneal dissemination were grouped into tubercular (TB), 40; nodular (ND), 31; diffuse (DF) type, 19; and others, 6, respectively, by the gross findings. Sixty-three patients underwent RST. Fifty-nine patients received CHPP by 10-liter heated saline. Thirty patients underwent intra-aortic catheterization for the IA-chemo. The 1-year and 2-year survival rate (1-ysr and 2-ysr) of the RST(+) group were 47% and 10% significantly greater than the 9% and 0% of the RST(-) group (p<0.001). The 1-ysr and 2-ysr of the CHPP(+) group were 37% and 11% significantly greater than the 27% and 0% of the CHPP(-) group (p=0.04). In the TB type the 1-ysr and 2-ysr of the former was 43% and 8% significantly greater than the 15% and 0% of the latter (p=0.04). But there was no significant difference in survival time between the CHPP(+) and the CHPP(-) group in the ND type (p=0.22) or in the DF type (p=0.42). The 1-ysr and 2-ysr of the IA-chemo(+) group were 49% and 19% significantly greater than the 27% and 2% of the IA-chemo(-) group (p<0.01). In the DF type the 1-ysr and 2-ysr of the former was 50% and 33% significantly greater than the 8% and 0% of the latter (p=0.02). However, there was no significant difference in survival time between the IA-chemo(+) and the IA-chemo(-) group in the TB type (p=0.06) or in the ND type (p=0.50). Moreover, the effect of the combination therapy of CHPP and IA-chemo (the sandwich therapy, SDW) were examined. The 1-ysr and 2-ysr of the SDW(+) group were 49% and 22% significantly greater than the 24% and 0% of the SDW(-) group (p=0.002). The sandwich therapy should be performed in addition to cytoreductive surgery for improvement of prognosis in the patient with intractable peritoneal dissemination.

Related Articles

Journal Cover

May 1996
Volume 3 Issue 3

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Fujimura T, Yonemura Y, Kawamura T, Nojima N, Satoh T, Hirono Y, Kinami S, Fushida S, Nishimura G, Miwa K, Miwa K, et al: Cytoreductive surgery and sandwich therapy with chemohyperthermic peritoneal perfusion and intra-aortic chemotherapy for peritoneal dissemination in gastric cancer. Oncol Rep 3: 513-517, 1996
APA
Fujimura, T., Yonemura, Y., Kawamura, T., Nojima, N., Satoh, T., Hirono, Y. ... Miyazaki, I. (1996). Cytoreductive surgery and sandwich therapy with chemohyperthermic peritoneal perfusion and intra-aortic chemotherapy for peritoneal dissemination in gastric cancer. Oncology Reports, 3, 513-517. https://doi.org/10.3892/or.3.3.513
MLA
Fujimura, T., Yonemura, Y., Kawamura, T., Nojima, N., Satoh, T., Hirono, Y., Kinami, S., Fushida, S., Nishimura, G., Miwa, K., Miyazaki, I."Cytoreductive surgery and sandwich therapy with chemohyperthermic peritoneal perfusion and intra-aortic chemotherapy for peritoneal dissemination in gastric cancer". Oncology Reports 3.3 (1996): 513-517.
Chicago
Fujimura, T., Yonemura, Y., Kawamura, T., Nojima, N., Satoh, T., Hirono, Y., Kinami, S., Fushida, S., Nishimura, G., Miwa, K., Miyazaki, I."Cytoreductive surgery and sandwich therapy with chemohyperthermic peritoneal perfusion and intra-aortic chemotherapy for peritoneal dissemination in gastric cancer". Oncology Reports 3, no. 3 (1996): 513-517. https://doi.org/10.3892/or.3.3.513